Skip to main content Accessibility help
×
Home

P03-359 Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Long-Acting Injectable in Relapse Prevention in Patients with Bipolar I Disorder

  • S. Montgomery (a1), E. Vieta (a2), A.H. Sulaiman (a3), R. Cordoba (a4), B. Huberlant (a5), A. Schreiner (a6) and G. Martinez (a7)...

Abstract

Objectives

To evaluate risperidone long-acting injectable (RLAI) versus placebo in prevention of mood episodes in adults with bipolar I disorder.

Methods

A 12-week open-label period with RLAI (N=585) was followed by an 18-month randomized, double-blind period with RLAI (25, 37.5 or 50 mg/2 weeks; N=137) or placebo (N=140); a third group (N=138) was randomized to olanzapine for reference and exploratory comparisons. Primary efficacy endpoint: time to relapse of any mood episode for risperidone LAI vs. placebo in the double-blind period (Kaplan-Meier analysis). Relapse was defined by criteria including DSM diagnosis, further treatment, hospitalisation, or Clinical Global Impression score ≥4 combined with YMRS or MADRS >12.

Results

Dosing was fixed during the double-blind period at patients’ final open-label dose (25 mg, 66%; 37.5 mg, 31%; 50 mg, 4%). Time to recurrence (any mood episode) was longer with RLAI versus placebo (log-rank test stratified by region and patient type, p=0.062; stratified by region only, p=0.032); the difference was significant for time to recurrence of elevated mood episodes (p=0.005) but not depressive episodes (p=0.587). Discontinuations due to adverse events (AEs) occurred in 2% of patients in the open-label period, and 4% and 1% in the RLAI and placebo groups, respectively, in the double-blind period. The most frequently reported AE in the open-label period was insomnia (15%). During double-blind treatment, the most frequently reported AEs with RLAI were weight increased (24%; placebo, 9%) and insomnia (16%; placebo, 17%).

Table 1.Type of recurrence

Type of episode, n (%)Risperidone LAI (N=135)Placebo (N=138)
All mood episodes52 (38.5)77 (55.8)
Elevated mood episode27 (20.0)54(39.1)
Hypomanic2(1.5)4 (2.9)
Manic17(12.6)43(31.2)
Mixed8 (5.9)7(5.1)
Depressive25(18.5)23(16.7)

Conclusion

RLAI significantly delayed time to relapse of elevated mood episodes and was well tolerated.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      P03-359 Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Long-Acting Injectable in Relapse Prevention in Patients with Bipolar I Disorder
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      P03-359 Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Long-Acting Injectable in Relapse Prevention in Patients with Bipolar I Disorder
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      P03-359 Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Long-Acting Injectable in Relapse Prevention in Patients with Bipolar I Disorder
      Available formats
      ×

Copyright

P03-359 Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Long-Acting Injectable in Relapse Prevention in Patients with Bipolar I Disorder

  • S. Montgomery (a1), E. Vieta (a2), A.H. Sulaiman (a3), R. Cordoba (a4), B. Huberlant (a5), A. Schreiner (a6) and G. Martinez (a7)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

P03-359 Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Long-Acting Injectable in Relapse Prevention in Patients with Bipolar I Disorder

  • S. Montgomery (a1), E. Vieta (a2), A.H. Sulaiman (a3), R. Cordoba (a4), B. Huberlant (a5), A. Schreiner (a6) and G. Martinez (a7)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *